# Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

> **NCT03101748** · PHASE1,PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Breast Inflammatory Carcinoma
- Locally Advanced Breast Carcinoma
- Metastatic Breast Carcinoma
- Stage III Breast Cancer AJCC v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Neratinib
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pertuzumab
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT03101748
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-19
- **Primary completion:** 2025-05-13
- **Final completion:** 2025-05-13
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** \<75% accrued
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03101748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03101748, "Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03101748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*